Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors

B. A. Silver, A. L. Barlock, Marc E Lippman, T. Anderson, R. I. Fisher

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

We have conducted a broad phase II clinical trial a chlorozotocin in 74 patients including 28 with malignant melanoma, 18 with breast cancer, nine with non-Hodgkin's lymphoma, six with nonseminomatous testicular cancer, five with ovarian cancer, four with sarcoma, three with non-beta islet cell carcinoma of the pancreas, and one with anaplastic carcinoma of the thyroid. Objective responses were noted only in 15% of the patients with melanoma and in 11% of the patients with non-Hodgkin's lymphoma. Significant leukopenia and thrombocytopenia were observed only in previously treated patients. Chlorozotocin does not appear to offer clinically significant advantages over other currently available nitrosoureas.

Original languageEnglish
Pages (from-to)1229-1230
Number of pages2
JournalCancer Treatment Reports
Volume66
Issue number5
StatePublished - Sep 20 1982
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Silver, B. A., Barlock, A. L., Lippman, M. E., Anderson, T., & Fisher, R. I. (1982). Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors. Cancer Treatment Reports, 66(5), 1229-1230.